Biotech expert Leen Kawas discussed the drivers of high drug development costs. She also offered strategies to streamline the ...

This approach enables an ongoing dialogue between the regulatory body and drug developers. Expediting the review process ...

Zeid Barakat began the discussion by highlighting how well-executed CMC can be a key strategic asset, enabling drug supply to ...